$30.8M funds Cambrian Bio’s bid to preserve resilience in aging
Cambrian Bio received up to $30.8 million from ARPA-H to test an mTORC1-selective inhibitor aimed at preserving intrinsic capacity in older adults. The program will use ARPA-H's PROSPR framework to evaluate resilience-focused endpoints rather than single-disease outcomes.
Why it mattersARPA-H awarded $30.8M to test an mTORC1-selective therapy under PROSPR.
Entities Mentioned
Cambrian Bio